• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    SC 13G/A 1 Omniab093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: OmniAb, Inc. Title of Class of Securities: Common Stock CUSIP Number: 68218J103 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 68218J103 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 8,819,762** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 8,819,762** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,819,762** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing Item 1. (a). Name of Issuer: OmniAb, Inc. ("OmniAb") (b). Address of Issuer's Principal Executive Offices: 5980 Horton Street, Suite 600 Emeryville, CA 94608 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 68218J103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 8,784,186 shares or 7.4% of the shares outstanding of OmniAb Common Stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of any one such Managed Portfolio does not exceed 5% of the class of securities. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 11/14/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary
    Get the next $OABI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Leadership Updates

    Live Leadership Updates

    See more
    • OmniAb Appoints Steve Love to its Board of Directors

      OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

      11/1/23 9:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Financials

    Live finance-specific insights

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb to Report First Quarter 2025 Financial Results on May 8

      OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2025 financial results and business updates       Date:   Thursday, May 8, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 96760    

      4/14/25 8:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

      3/18/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      11/14/24 4:06:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

      SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

      7/2/24 5:00:16 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Introduces the xPloration® Partner Access Program

      High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb's Partners for Use in Their Own Laboratories OmniAb, Inc. (NASDAQ:OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb's proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508776052/en/ "xPloration has been a core

      5/8/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

      ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")) for the development of a novel bispecific antibody drug conjugate ("bsADC") program targeting solid tumors. The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC") linker technology and conjugation expertise to support next-generation therapeutic discovery. "This partnership brings together two highly co

      5/5/25 1:00:00 AM ET
      $OABI
      $VACH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OABI
    SEC Filings

    See more
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by OmniAb Inc.

      SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

      5/14/25 12:32:07 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by OmniAb Inc.

      10-Q - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:51:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:11:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on OmniAb with a new price target

      RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

      11/29/23 7:31:15 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • The Benchmark Company initiated coverage on OmniAb with a new price target

      The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

      4/21/23 7:43:22 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Craig Hallum initiated coverage on OmniAb with a new price target

      Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

      4/13/23 9:08:06 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care